GSK's regulatory filing for expanded use of RSV vaccine, Arexvy, in adults aged 18 years and older has been accepted for ...

Though the vaccine’s sales rose consistently till 2022, it started witnessing sluggish sales from 2024. Sales of the vaccine ...

GSK has applied to the European Medicines Agency to expand use of its respiratory syncytial virus (RSV) vaccine to adults ...

GSK GSK stock has risen 21.5% in the past six months. The consistently strong performance of the Specialty Medicines unit, ...

London: GSK plc has announced that the European Medicines Agency (EMA) has accepted the company's regulatory application to ...

GSK plc GSK announced that the European Medicines Agency (EMA) has accepted the regulatory application seeking approval to expand the use of its adjuvanted recombinant respiratory syncytial virus ...

The EMA’s acceptance of the application to extend the use of Arexvy represents a significant step in broadening the vaccine’s reach to a wider adult population. Arexvy was the first RSV ...

The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a ...

EMA accepts for regulatory review GSK’s RSV vaccine, Arexvy to expand use in adults 18 years and older: London, UK Saturday, June 14, 2025, 10:00 Hrs [IST] GSK plc announced tha ...

Arexvy was the first RSV vaccine approved in the European Economic Area for the prevention of lower respiratory tract disease caused by RSV in adults aged 60 and older, and for those aged 50 to 59 ...

Dublin, May 29, 2025 (GLOBE NEWSWIRE) -- The "Abrysvo or Arexvy Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" report has been added to ResearchAndMarkets.com's ...